Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (COPD), diseases of the retina such as age-related macular degeneration (AMD), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (PNH). Apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. We call this approach Complement Immunotherapy.